Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.
about
The gene therapy journey for hemophilia: are we there yet?State-of-the-art human gene therapy: part I. Gene delivery technologiesProgress and prospects: immune responses to viral vectorsA universal system to select gene-modified hepatocytes in vivoEvaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine modelsAdenoviral Vectors for Hemophilia Gene TherapyThe pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaquesInfluence of immune responses in gene/stem cell therapies for muscular dystrophies.Progress towards gene therapy for haemophilia B.Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.Gene therapy with mitochondrial heat shock protein 70 suppresses visual loss and optic atrophy in experimental autoimmune encephalomyelitis.Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines.Activation of the cellular unfolded protein response by recombinant adeno-associated virus vectors.LHON gene therapy vector prevents visual loss and optic neuropathy induced by G11778A mutant mitochondrial DNA: biodistribution and toxicology profile.Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial.Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liverLarge-scale recombinant adeno-associated virus productionPerinatal gene transfer to the liver.Gene therapy for the nervous system: challenges and new strategies.AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypesImmunosuppression decreases inflammation and increases AAV6-hSERCA2a-mediated SERCA2a expressionThe threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing.Ac45 silencing mediated by AAV-sh-Ac45-RNAi prevents both bone loss and inflammation caused by periodontitis.Gene Therapy for Duchenne muscular dystrophy.An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8+ T CellsSite-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In VivoStrategies to circumvent humoral immunity to adeno-associated viral vectors.Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.Immune responses to AAV vectors: overcoming barriers to successful gene therapyA concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapySuperior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid.CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypesHuman Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.Helper-Dependent Adenoviral Vectors.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesAAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
P2860
Q26823818-187E1458-C51A-4544-BD7D-ADE530B37548Q26825575-C2BF65E1-6E34-437A-BBC6-1D36E9B51BA2Q28264531-16C14A2C-AB79-4253-95E7-FEEB56FA9F25Q28468539-FF15B827-7835-4A09-9764-B765FF010FB6Q33623549-2E945B68-7BA4-4A02-919F-A3EEE37BE926Q33690648-4F90E07E-570F-44FC-941C-E5FBE0A71DDDQ33730459-7EE369F4-2270-4058-9F32-7CA22EEA1030Q33736192-7FD3333D-BC4D-4185-BE2C-DB727F4F108EQ33844184-4BD3F8FF-FD04-4D29-B844-51B48EE08E08Q33881920-559B38C6-AED9-4F89-B9C5-55BB6C5B44B5Q33902499-BD109DC1-24BA-4324-A2C8-4E6869EF340AQ33938435-65CDB50A-2E86-4194-A3C8-FB0AE5E69A57Q34069978-4883E4DD-C134-4F48-B5CE-77614ABEF3CEQ34370111-22024943-438E-4AA1-945F-E9163785B05BQ34382965-EFF139FA-97AD-4DAA-B53D-7F93F31554B4Q34548352-262EDBE4-0C0D-49E9-B27A-477A0711750BQ34600009-580F595D-71ED-4CB3-933D-C1975F213004Q34700126-D19959BC-3CA3-4FEF-8E2C-4D50502F381BQ34843835-7061424A-F6A3-4E67-BBD8-D126578A6A61Q34982857-F976C76B-4EF0-4750-A31E-1C02E46BC68BQ35238390-E6D7D454-EEFB-44CD-9C77-BE70E29DD59FQ35340196-21C2A78B-0661-46E7-BDD0-A3F0D096FCF4Q36106408-A9D92650-8768-4FD5-956E-F48D15F5214FQ36114228-2589E857-34AE-4B9D-BDCC-BA681A6B57ADQ36155013-653F4610-B7EA-497B-A87C-2BB4176E4480Q36207488-EEBD0FEE-243C-44FE-94A4-E7BC9BFACE9FQ36295934-722D6F99-4443-4301-888F-FC73DB29E881Q36365372-A9C36D91-EB56-4075-829C-D33609C4D4EDQ36367714-B3593590-04B3-4F08-8A71-DAAD102D4D5AQ36398678-7287947D-5F32-4AE9-ABE4-F9AEBC1BA4CEQ36638203-77070FC8-70E0-4109-8C57-C2EF1B36ADDBQ36709834-DE528B32-B87C-49B3-89AE-611792201698Q36983740-07C68BC2-E409-4854-9BBF-5878A1B3CAA5Q37012949-91FA4231-E4C5-4561-A1E7-2DF518B9FBFFQ37043507-1692D3D6-FC5E-45CC-B914-F300D828B41DQ37277305-4BB0DB6F-A46A-48DD-B43F-4C08095256BDQ37384103-C39210D6-A6CA-466A-992B-3E76A5CF2A86Q37582126-68059D18-F5E8-4FAA-A5BA-85C7A41D3A8BQ37621530-B2CB4C2F-859E-4101-AD01-B554E921106EQ37825907-CEED2A69-495D-4227-8876-72E6461E42C4
P2860
Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Capsid antigen presentation fl ...... deno-associated viral vectors.
@en
Capsid antigen presentation fl ...... deno-associated viral vectors.
@nl
type
label
Capsid antigen presentation fl ...... deno-associated viral vectors.
@en
Capsid antigen presentation fl ...... deno-associated viral vectors.
@nl
prefLabel
Capsid antigen presentation fl ...... deno-associated viral vectors.
@en
Capsid antigen presentation fl ...... deno-associated viral vectors.
@nl
P2093
P2860
P356
P1476
Capsid antigen presentation fl ...... deno-associated viral vectors.
@en
P2093
Ashley N Mentlik
Daniel J Hui
Etiena Basner-Tschakarjan
Federico Mingozzi
Gary C Pien
Jonathan D Finn
Katherine A High
Nicole C Hasbrouck
Samuel L Murphy
Shangzhen Zhou
P2860
P304
P356
10.1172/JCI36891
P407
P577
2009-05-11T00:00:00Z